Skip to Main Content

Paper Details

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Eur J Cancer
130
2017
BRAF, BRAFV600, BRAFV600 mutant, MEK, Patients, Pembrolizumab, advanced melanoma, ipilimumab, patients, pembrolizumab
Author NameAffiliation
Reinhard DummerUniversity of Zurich
Reinhard DummerUniversity of Zurich
Dirk SchadendorfUniversity Hospital Essen
Caroline RobertGustave Roussy and Paris-Sud University
Anna C PavlickNew York University Cancer Institute
Rene GonzalezUniversity of Colorado Denver
Antoni RibasUniversity of California Los Angeles
Antoni RibasUniversity of California Los Angeles
  • 1 - 8

Datasets

Release 1.2